after you join the study, you will complete a consent form and provide basic information about your health history.

the study team will perform a physical examination, collect blood samples, and obtain imaging studies to document the current status of your melanoma.

on the first day of treatment you will receive two types of medication:

momelotinib (brand name omjjara) as an oral tablet that you will swallow with water, and

an anti‑pd‑1 antibody (nivolumab or pembrolizumab) given by intravenous infusion, which means the drug is delivered through a vein over a short period.

the exact dose and frequency of each medication are defined in the study protocol and will be explained by the study staff.

you will take the momelotinib tablet every day, at the same time each day, for the duration of the study.

the tablet is film‑coated and comes in strengths of 100 mg, 150 mg, or 200 mg; the specific strength and number of tablets per day are determined by the dose level assigned to you.

if you miss a dose, you should follow the instructions provided by the study team.

you will receive an infusion of either nivolumab or pembrolizumab according to the schedule used in the study, which is typically every 2 or 3 weeks.

each infusion is administered in a clinic or hospital setting; the medication is mixed with a small amount of fluid and delivered through a needle placed in a vein.

the infusion takes about 30 to 60 minutes, during which you will be monitored for any immediate reactions.

during the first few treatment cycles you will have weekly visits for blood draws and other laboratory tests to check how your body is responding to the medications.

the study team will assess any side effects (also called adverse events) and record their severity using a standardized grading system.

additional assessments, such as physical exams and vital‑sign checks, will be performed at each visit.

in the early part of the trial (phase ib) the investigators will evaluate the safety of the combination and may adjust the momelotinib dose to find the maximum tolerated dose (mtd) and the recommended phase ii dose (rp2d).

if dose adjustments are needed because of side effects, you will be instructed on how to modify the oral tablet dose while continuing the infusion schedule.

once the recommended dose is established, you will continue taking momelotinib daily and receiving anti‑pd‑1 infusions for up to 6 months.

this period corresponds to approximately 4, 6, 8, or 12 infusion cycles, depending on the interval used for the anti‑pd‑1 antibody.

the primary goal during this phase is to observe the anti‑tumor activity of the combination.

you will undergo imaging scans (such as ct or mri) at month 3 and month 6 after the first dose to evaluate the tumor response.

the scans will be reviewed using standard criteria (recist v1.1) to classify the outcome as complete response, partial response, stable disease, or progressive disease.

treatment will end when you have completed the planned 6‑month period, or earlier if the disease progresses, side effects become unacceptable, or you choose to withdraw consent.

the study team will discuss the reason for stopping treatment and will provide guidance on the next steps.

after treatment stops, you will have follow‑up visits once a year for several years.

these visits will include safety assessments, quality‑of‑life questionnaires (qlq‑c30), and any additional tests the investigators deem necessary.

the follow‑up period continues until the last patient enrolled reaches the study end date.